The adalimumab market is expected to show negative growth during the forecast period 2020-2026. Adalimumab is sold by AbbVie Inc., under the brand name of Humira. It was the first approved treatment of rheumatoid arthritis in the US in 2002 and in the EU in 2003. Humira is a biological therapy administered as a subcutaneous injection. In 2019, Humira accounted for around 58% of the total net revenue of AbbVie Inc., with revenue of $19.1 billion as compared to $19.9 billion in 2018. The high cost of the Humira is able to provide a significant market to the adalimumab market. It is due to the high annual costs of the drug. For instance, in the US, the annual cost of using Humira was around $19,000 in 2012 which has risen to around $38,000 with rebates in 2018 and about $50,000 without rebates.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/adalimumab-market

The global adalimumab market is segmented based on disease and type. On the basis of disease, the market is segmented into rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and others. Rheumatoid arthritis is expected to hold the major market share during the forecast period. By type, the market is bifurcated into branded and generic drugs. Till 2023, branded drugs are expected to have a major market share and a significant market growth will be witnessed until 2023 however after that a steep downfall is expected in the branded drug revenue. However, generic drugs are expected to grow with a lucrative growth rate during the forecast period.  

Secondary Sources Include:
Financial reports of companies involved in the market
Whitepapers research-papers, and news blogs
Company websites and their product catalogue

The report is intended for a healthcare service provider, medical device companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

A Full Report Global Adalimumab Market is Available at: https://www.omrglobal.com/industry-reports/adalimumab-market


Market Overview and Insights

Scope of the Report
Analyst Insight & Current Market Trends
Key Findings
Recommendations
Conclusion
Rules & Regulations

Market Segmentation

Global Adalimumab Market by Product Type
Topical Stretch Mark Minimizers
Pregnancy Test Kits
Toning and Body Firming Gel
Restructuring Gel
Breast Cream
Others (Itching Prevention Cream, Stressed Leg Products)
Global Adalimumab Market by Distribution Channels
Hospital Pharmacies
Retail Stores 
Online Channels


















Company Profiles
AbbVie Inc.
 Alvotech hf
 Amgen Inc.
Bio-Thera Solutions Ltd. 
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Cadila Healthcare Ltd.
Emcure Pharmaceuticals Ltd.
Fujifilm Kyowa Kirin Biologics Co. Ltd.
Hetero Healthcare Ltd.
Innovent Biologics, Inc. 
Merchant Logo
Novartis International AG (Sandoz)
Pfizer Inc. 
Reliance Life Sciences Pvt. Ltd.
Samsung Bioepis Co. Ltd 
Terumo Corp.
Torrent Pharmaceuticals Ltd.

Market Determinants 
Motivators
Restraints
Opportunities 

Medical Food Market – Segment by Region 
North America           
United States 
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Europe   
North-American
Japan
India
Rest of North-American
Rest of the World
Latin America
Middle East and Africa

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/adalimumab-market


About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404